Genetic rearrangements of KMT2A result in oncogenic fusion proteins, here, t (17;19)/TCF3-HLF, haploidy or low hypodiploidy are high-risk biomarkers in AML [19]. This evidence concerns the gene TCF3 and acute myeloid leukemia.